Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non Operating Income (2017 - 2024)

Historic Other Non Operating Income for Aclaris Therapeutics (ACRS) over the last 8 years, with Q2 2024 value amounting to $1.9 million.

  • Aclaris Therapeutics' Other Non Operating Income fell 1682.99% to $1.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $8.4 million, marking a year-over-year increase of 3128.73%. This contributed to the annual value of $8.5 million for FY2023, which is 18883.23% up from last year.
  • As of Q2 2024, Aclaris Therapeutics' Other Non Operating Income stood at $1.9 million, which was down 1682.99% from $2.0 million recorded in Q1 2024.
  • In the past 5 years, Aclaris Therapeutics' Other Non Operating Income registered a high of $2.3 million during Q3 2023, and its lowest value of -$851000.0 during Q3 2021.
  • Its 5-year average for Other Non Operating Income is $763722.2, with a median of $320000.0 in 2020.
  • As far as peak fluctuations go, Aclaris Therapeutics' Other Non Operating Income tumbled by 33865.98% in 2021, and later skyrocketed by 152247.19% in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Other Non Operating Income (Quarter) stood at -$219000.0 in 2020, then surged by 140.64% to $89000.0 in 2021, then soared by 1522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then fell by 14.66% to $1.9 million in 2024.
  • Its last three reported values are $1.9 million in Q2 2024, $2.0 million for Q1 2024, and $2.2 million during Q4 2023.